CLL, chronic lymphocytic leukemia; Dx, diagnoses; F, female; FCL, follicular non-Hodgkin lymphoma; M, male; MCL, mantle cell lymphoma; MDS, myelodysplastic syndrome; MF, myelofibrosis; MM, multiple myeloma; N, no; n.a., not applicable; NED, no evidence of disease status; UPN, unique patient number; Y, yes.

#, number of prior regimens. Res, disease response: 1° R, primary refractory; S, sensitive to last regimen; and R, refractory to last regimen. Pre-HCT, indicates disease status at time of low-intensity transplant: Res, response to EPOCH-F(R): PR, partial response; CR, complete response; SD, stable disease; and hCR, hematologic CR.

Acute GVHD score of skin (s), gut (g), and liver (l); Gr, overall grade (0-4). Late acute GVHD, manifested as elevated liver transaminase levels (tr), skin (s), or gut involvement (g). Chronic GVHD sites of involvement: oral (o), skin (s), eye (e), vaginal (v), and lung (l).

Overall outcome for last tumor staging: PD, progressive disease; CR, complete remission; mCR, molecular CR; and SD, stable disease. Ongoing survival, in days post-HCT (+). Death, day post-HCT; cause due to PD, presumed pulmonary embolus (PE), or myocardial infarction (MI).

Risk of progressive disease post-HCT: level 1, low risk; level 2, standard risk.